Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : NEXL -- Ignore unavailable to you. Want to Upgrade?

To: bob jaremsek who wrote (1356)	4/15/1998 8:07:00 PM
From: bob jaremsek	Read Replies (1) \| Respond to of 1704

And now from Reuters: VIMRx starts wound healing Phase I trial WILMINGTON, Del., April 15 (Reuters) - VIMRx Pharmaceuticals Inc said Wednesday that it had started a Phase I clinical trial on VM301, a novel compound that has shown promising wound-healing activity when applied topically in preclinical studies. The studies are designed to evaluate the safety of the compound on both normal and broken skin/ VIMRX is developing VM301 for the treatment of both partial and full thickness wounds, including burns, surgical wounds, diabetic skin ulcers, and decubitus ulcers (bed sores). VIMRx said the compound has also shown anti-inflammatory properties, which may expand its clinical potential in the future. More Quotes and News: VIMRX Pharmaceuticals Inc (Nasdaq:VMRX - news) Related News Categories: health